{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:06:28Z","timestamp":1767841588128,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.vaccine.2011.08.006","type":"journal-article","created":{"date-parts":[[2011,8,19]],"date-time":"2011-08-19T17:32:52Z","timestamp":1313775172000},"page":"7644-7650","source":"Crossref","is-referenced-by-count":24,"title":["Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population"],"prefix":"10.1016","volume":"29","author":[{"given":"Carlos","family":"Casta\u00f1eda-Orjuela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson","family":"Alvis-Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel Jos\u00e9","family":"Paternina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"De la Hoz-Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"July (Suppl. 1)","key":"10.1016\/j.vaccine.2011.08.006_bib0005","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0264-410X(99)00122-X","article-title":"The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known","volume":"17","author":"Fedson","year":"1999","journal-title":"Vaccine"},{"issue":"April (13)","key":"10.1016\/j.vaccine.2011.08.006_bib0010","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.285.13.1729","article-title":"Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995\u20131998: opportunities for prevention in the conjugate vaccine era","volume":"285","author":"Robinson","year":"2001","journal-title":"JAMA"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2011.08.006_bib0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1055\/s-2005-925523","article-title":"Streptococcus pneumoniae: epidemiology, risk factors, and clinical features","volume":"26","author":"Ortqvist","year":"2005","journal-title":"Semin Respir Crit Care Med"},{"issue":"May\u2013June (3)","key":"10.1016\/j.vaccine.2011.08.006_bib0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/clinids\/11.3.498","article-title":"Acute respiratory infection in children of developing countries: challenge of the 1990s","volume":"11","author":"Monto","year":"1989","journal-title":"Rev Infect Dis"},{"issue":"March\u2013April (2)","key":"10.1016\/j.vaccine.2011.08.006_bib0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/clinids\/7.2.133","article-title":"Invasive pneumococcal infections: incidence, predisposing factors, and prognosis","volume":"7","author":"Burman","year":"1985","journal-title":"Rev Infect Dis"},{"issue":"July\u2013August (4)","key":"10.1016\/j.vaccine.2011.08.006_bib0030","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/clinids\/11.4.586","article-title":"Community-acquired pneumonia requiring hospitalization: 5-year prospective study","volume":"11","author":"Marrie","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.006_bib0035","unstructured":"World Health Organization. Estimates of disease burden and cost-effectiveness. Geneva; 2008 [cited 2010 junio]. Available from: http:\/\/www.who.int\/immunization_monitoring\/burden\/estimates_burden\/en\/index.html."},{"key":"10.1016\/j.vaccine.2011.08.006_bib0040","unstructured":"DANE. Cuadro 5. Defunciones, por grupos de edad y sexo, seg\u00fan lista de causas agrupadas 6\/67 CIE-1 de OPS. A\u00f1o 2007. Bogota, D.C.: DANE; 2007 [cited 2011 May]. Available from: http:\/\/www.dane.gov.co\/daneweb_V09\/index.php?option=com_content&view=article&id=205&Itemid=119."},{"key":"10.1016\/j.vaccine.2011.08.006_bib0045","unstructured":"Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(April (RR-8)):1\u201324."},{"issue":"June (17\u201318)","key":"10.1016\/j.vaccine.2011.08.006_bib0050","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.vaccine.2003.11.038","article-title":"Pneumococcal vaccines: an update on current strategies","volume":"22","author":"Bogaert","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.006_bib0055","series-title":"Pneumococcal vaccine for older people","author":"NHS","year":"2004"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2011.08.006_bib0235","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.clinthera.2010.07.019","article-title":"Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the United States during an influenza pandemic","volume":"32","author":"Dhankhar","year":"2010","journal-title":"Clin Ther"},{"issue":"May (17\u201318)","key":"10.1016\/j.vaccine.2011.08.006_bib0065","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/S0264-410X(02)00112-3","article-title":"Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults","volume":"20","author":"Watson","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.006_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2296-1-1","article-title":"Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials","volume":"1","author":"Moore","year":"2000","journal-title":"BMC Fam Pract"},{"issue":"August (23\u201324)","key":"10.1016\/j.vaccine.2011.08.006_bib0075","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1016\/j.vaccine.2003.08.050","article-title":"The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials","volume":"22","author":"Conaty","year":"2004","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2011.08.006_bib0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1023\/B:EJEP.0000024701.94769.98","article-title":"The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses","volume":"19","author":"Melegaro","year":"2004","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2011.08.006_bib0085","first-page":"CD000422","article-title":"Vaccines for preventing pneumococcal infection in adults","volume":"1","author":"Moberley","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2011.08.006_bib0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00019053-200017060-00005","article-title":"Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium","volume":"17","author":"De Graeve","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2011.08.006_bib0095","first-page":"38","article-title":"The impact of pneumococcal disease on adults living in Bogota, Colombia, 2008","volume":"12","author":"Castaneda-Orjuela","year":"2010","journal-title":"Rev Salud Publica (Bogota)"},{"key":"10.1016\/j.vaccine.2011.08.006_bib0100","unstructured":"DANE. Proyecciones de Poblaci\u00f3n Municipales. Bogot\u00e1, D.C.: DANE; 2009 [2009 Feb 23]. Available from: http:\/\/www.dane.gov.co\/index.php?option=com_content&task=category&sectionid=16&id=497&Itemid=995."},{"key":"10.1016\/j.vaccine.2011.08.006_bib0105","unstructured":"PROFAMILIA. Encuesta Nacional de Demografia y Salud Bogota D.C.; 2005."},{"issue":"November (5)","key":"10.1016\/j.vaccine.2011.08.006_bib0110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijantimicag.2006.07.016","article-title":"Aetiology and resistance patterns of community-acquired pneumonia in Leon, Nicaragua","volume":"28","author":"Matute","year":"2006","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.vaccine.2011.08.006_bib0115","first-page":"731","article-title":"Neumon\u00eda adquirida en la comunidad en acncianos que requieren internaci\u00f3n.Cuadro cl\u00ednico y pron\u00f3stico","volume":"59","author":"Diaz","year":"1999","journal-title":"Medicina (Arg)"},{"issue":"1","key":"10.1016\/j.vaccine.2011.08.006_bib0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4067\/S0717-73482003000100002","article-title":"Mortalidad por enfermedades respiratorias en Chile durante 1999","volume":"19","author":"Szot","year":"2003","journal-title":"Rev Chil Enferm Respir"},{"issue":"2","key":"10.1016\/j.vaccine.2011.08.006_bib0125","first-page":"86","article-title":"Meningoencefalitis bacterianas en Cuba","volume":"39","author":"Dickinson","year":"2001","journal-title":"Rev Cubana Hig Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2011.08.006_bib0130","first-page":"32","article-title":"Meningoencefalitis bacterianas en el adulto mayor cubano 1998\u20132000","volume":"18","author":"Dickinson Meneses","year":"2002","journal-title":"Geri\u00e1trika"},{"issue":"September (3B)","key":"10.1016\/j.vaccine.2011.08.006_bib0135","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1590\/S0004-282X1997000400012","article-title":"Clinical and laboratory characteristics of pyogenic meningitis in adults","volume":"55","author":"Gomes","year":"1997","journal-title":"Arq Neuropsiquiatr"},{"issue":"September (3A)","key":"10.1016\/j.vaccine.2011.08.006_bib0140","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1590\/S0004-282X2008000400014","article-title":"Acute bacterial meningitis caused by Streptococcus pneumoniae resistant to the antimicrobian agents and their serotypes","volume":"66","author":"Rossoni","year":"2008","journal-title":"Arq Neuropsiquiatr"},{"issue":"August (36)","key":"10.1016\/j.vaccine.2011.08.006_bib0145","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1016\/j.vaccine.2009.05.061","article-title":"Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions","volume":"27","author":"Ogilvie","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.006_bib0150","unstructured":"WHO Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva; 2001"},{"issue":"July\u2013August (4)","key":"10.1016\/j.vaccine.2011.08.006_bib0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/S019594170005637X","article-title":"Cost effectiveness and cost benefit of vaccination against pneumococcal pneumonia: implications for clinical practice","volume":"3","author":"Willems","year":"1982","journal-title":"Infect Control"},{"issue":"September (10)","key":"10.1016\/j.vaccine.2011.08.006_bib0160","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM198009043031004","article-title":"Cost effectiveness of vaccination against pneumococcal pneumonia","volume":"303","author":"Willems","year":"1980","journal-title":"N Engl J Med"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2011.08.006_bib0165","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1086\/313977","article-title":"Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries","volume":"31","author":"Ament","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2011.08.006_bib0170","first-page":"133","article-title":"Cost effectiveness of pneumococcal vaccine (author's transl)","volume":"29","author":"Levy","year":"1981","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"February (5)","key":"10.1016\/j.vaccine.2011.08.006_bib0175","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/jama.1981.03310300027014","article-title":"A cost\u2013benefit analysis of immunization for pneumococcal pneumonia","volume":"245","author":"Patrick","year":"1981","journal-title":"JAMA"},{"issue":"September\u2013October (5)","key":"10.1016\/j.vaccine.2011.08.006_bib0180","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0213-9111(02)71948-1","article-title":"Cost-effectiveness of 23-valent antipneumococcical vaccination in Catalonia (Spain)","volume":"16","author":"Plans","year":"2002","journal-title":"Gac Sanit"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2011.08.006_bib0185","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0002-9343(99)00050-9","article-title":"Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia","volume":"106","author":"Ruiz-Gonzalez","year":"1999","journal-title":"Am J Med"},{"issue":"March (Suppl. 2)","key":"10.1016\/j.vaccine.2011.08.006_bib0190","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"October (9136)","key":"10.1016\/j.vaccine.2011.08.006_bib0195","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(98)02239-9","article-title":"Community-acquired pneumonia","volume":"352","author":"Brown","year":"1998","journal-title":"Lancet"},{"issue":"December (11)","key":"10.1016\/j.vaccine.2011.08.006_bib0200","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/425615","article-title":"The burden of community-acquired pneumonia in seniors: results of a population-based study","volume":"39","author":"Jackson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.006_bib0205","unstructured":"World Health Organization, 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008;83(October (42)):373\u201384."},{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.08.006_bib0240","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1503\/cmaj.080734","article-title":"Efficacy of pneumococcal vaccination in adults: a meta-analysis","volume":"180","author":"Huss","year":"2009","journal-title":"Can Med Assoc J"},{"issue":"October (15)","key":"10.1016\/j.vaccine.2011.08.006_bib0215","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jama.1993.03510150060030","article-title":"Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations","volume":"270","author":"Butler","year":"1993","journal-title":"JAMA"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2011.08.006_bib0220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1473-3099(03)00514-0","article-title":"Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence","volume":"3","author":"Mangtani","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2011.08.006_bib0225","first-page":"35","article-title":"The prophylaxis of nonhospital pneumonia using 23-valent pneumococcus vaccine in the military collectives","volume":"325","author":"Zhogolev","year":"2004","journal-title":"Voen Med Zh"},{"issue":"4","key":"10.1016\/j.vaccine.2011.08.006_bib0230","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF03256134","article-title":"Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France","volume":"6","author":"Standaert","year":"2008","journal-title":"Appl Health Economics Health Policy"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11012151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11012151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T16:59:52Z","timestamp":1543597192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11012151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":46,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0264410X11012151"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.08.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}